Full Length Research Paper
References
(CLSI) CLSI. Clinical and Laboratory Standards Institute Standards Development Policies and Process. M07-A102011. |
|
Aragon-Martinez OH, Isiordia-Espinoza MA, Galicia O, Romo SA, Gómez AG, Romano-Moreno S, Martinez-Morales F (2017). Measurement of levofloxacin in human plasma samples for a reliable and accessible drug monitoring. Clin. Biochem. 50(1):73-9. |
|
Artaza O, Méndez C, Holder R, Suárez J (2016). Redes Integradas de Servicios de Salud: el desafío de los hospitales. Santiago, Chile: Organización Panamericana de la Salud/Organización Mundial de la Salud, 2011. Available at: |
|
Barreto F, Ribeiro CBD, Hoff RB, Costa TD (2017) Development and validation of a high-throughput method for determination of nine fluoroquinolones residues in muscle of different animal species by liquid chromatography coupled to tandem mass spectrometry with low temperature clean up. J. Chromatograph. A.1521(Supplement C):131-9. |
|
Carvalho M, Maia A, Tiritan M, Castro P (2016). Bacterial degradation of moxifloxacin in the presence of acetate as a bulk substrate. J. Environ. Manag. 168:219-28. |
|
Cattaneo CA, Larcher LI, Acosta CA. Cattaneo CA, Larcher LI, Acosta CA.(2009) Aplicación de Dimensión Fractal al estudio de Sistemas Naturales. Mecánica Computacional, Numerical Methods for Simulation and Analysis in Bioengineering; Volume XXVII. (Number 44):2021-38. |
|
Cercenado E (2011). Enterococcus: resistencias fenotípicas y genotípicas y epidemiología en Espa-a. Enferm. Infecc. Microbiol. Clin. 29:59-65. |
|
Fari-a N, Sanabria R, Laspina F, Samudio M, de Figueredo L, de Kaspar HM (2007) Actividad in vitro de fluoroquinolonas en bacilos gramnegativos aislados de urocultivos de pacientes ambulatorios. Memorias del Instituto de Investigaciones en Ciencias de la Salud. 5(1). |
|
Jackson LC, Machado L, Hamilton ML (1998). Principios generales de la terapéutica antimicrobiana. Acta Méd. 8(1):13-27. |
|
Jorgensen JH, Turnidge JD (2015). Susceptibility test methods: dilution and disk diffusion methods. In Manual of Clinical Microbiology, Eleventh Edition. Am. Soc. Microbiol. 1253-1273. |
|
Juste Díez de Pinos JL, Adrover Rigó M, Ribas Sala J (2000). Levofloxacino, fluorquinolona de tercera generación. Farm Hospit. 24(5):288-295. |
|
Kao CY, Wu HM, Lin WH, Tseng CC, Yan JJ, Wang MC, Teng CH, Wu JJ (2016). Plasmid-mediated quinolone resistance determinants in quinolone-resistant Escherichia coli isolated from patients with bacteremia in a university hospital in Taiwan, 2001–2015. Sci. Rep. 6:32281. |
|
Mandell GL, Dolin JE, Mandell RL, Bennett JE, Dolin R, Mandell GL, Douglas JE, Mandell GL, DOLIN JE, Mandell RL, Bennett JE (2010). Enfermedades infecciosas: principios y práctica (No. 616.9). Elsevier |
|
Martínez P, Mercado M, Máttar S (2004). Actividad in vitro de moxifloxacina comparada con otros antibióticos frente a aislamientos nosocomiales de dos hospitales de Colombia. Universitas Medicas. 45:101-9. |
|
Medina-Morales DA, Machado-Duque ME, Machado-Alba JE (2015). Resistencia a antibióticos, una crisis global. Rev. Méd. Risaralda. 21(1):74-74. |
|
Meléndez P, Díaz J, Silva E, González P, Moreno E, Amaya P, Serrato N, Sáenz E (2005). Estudio comparativo de la actividad antimicrobiana de diferentes presentaciones comerciales de antibióticos de administración intravenosa a través de métodos in vitro. Rev. Colombiana. Cien. Químico-Farm. 34(2). |
|
Pastor-Sánchez R (2006). Alteraciones del nicho ecológico: resistencias bacterianas a los antibióticos. Gac. Sanit. 20:175-81. |
|
Pharmacopeia (2016). United States Pharmacopeia and National Formulary (USP 38–NF 33). Vol Section. 2016; 2:35-117. Available at: View |
|
Sato T, Yokota SI, Uchida I, Okubo T, Ishihara K, Fujii N, Tamura Y (2011). A fluoroquinolone-resistant Escherichia coli clinical isolate without quinolone resistance-determining region mutations found in Japan. Antimicrob. Agents Chemother. 55(8):3964-3965. |
|
Sun HY, Liao HW, Sheng MH, Tai HM, Kuo CH, Sheng WH (2016). Bioequivalence and in vitro antimicrobial activity between generic and brand-name levofloxacin. Diagn. Microbiol. Infect. Dis. 85(3):347-51. |
|
Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM (2005). Quinolones in 2005: an update. Clin. Microbiol. Infect. 11(4):256-280. |
|
Van Toi P, Pouplin T, Tho NDK, Phuong PN, Chau TTH, Thuong NTT, Heemskerk D, Hien TT, Thwaites GE (2017). High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis. J. Chromatogr. B. 1061:256-262. |
|
Yılmaz EÅž, AslantaÅŸ Ö (2017). Antimicrobial resistance and underlying mechanisms in Staphylococcus aureus isolates. Asian Pac. J. Trop. Med. 10(11):1059-1064. |
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0